Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 11 | 2025 | 318 | 2.600 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 11 | 2020 | 204 | 1.440 |
Why?
|
| Brachytherapy | 8 | 2025 | 126 | 1.410 |
Why?
|
| Breast Neoplasms | 15 | 2021 | 3110 | 1.050 |
Why?
|
| Chemoradiotherapy | 5 | 2020 | 326 | 1.030 |
Why?
|
| Radiotherapy Dosage | 10 | 2025 | 472 | 0.830 |
Why?
|
| Radiation Injuries | 5 | 2021 | 158 | 0.770 |
Why?
|
| Vaccines, DNA | 1 | 2020 | 19 | 0.630 |
Why?
|
| Endometrial Neoplasms | 3 | 2019 | 227 | 0.630 |
Why?
|
| Human papillomavirus 18 | 1 | 2020 | 22 | 0.630 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 45 | 0.620 |
Why?
|
| Safety | 1 | 2020 | 132 | 0.600 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 187 | 0.600 |
Why?
|
| Radiotherapy | 3 | 2016 | 320 | 0.560 |
Why?
|
| Radiometry | 2 | 2016 | 60 | 0.530 |
Why?
|
| Radiosurgery | 2 | 2021 | 317 | 0.520 |
Why?
|
| Cone-Beam Computed Tomography | 3 | 2020 | 72 | 0.450 |
Why?
|
| Female | 42 | 2025 | 48698 | 0.420 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 292 | 0.410 |
Why?
|
| Radiation Oncology | 3 | 2019 | 124 | 0.400 |
Why?
|
| Radiotherapy, Intensity-Modulated | 5 | 2016 | 188 | 0.390 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1173 | 0.390 |
Why?
|
| Radiotherapy, Conformal | 4 | 2020 | 88 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2018 | 1077 | 0.380 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 327 | 0.360 |
Why?
|
| Lymph Nodes | 2 | 2016 | 548 | 0.340 |
Why?
|
| Mastectomy, Segmental | 3 | 2011 | 107 | 0.340 |
Why?
|
| Middle Aged | 26 | 2024 | 27569 | 0.320 |
Why?
|
| Radiation Dosage | 3 | 2025 | 229 | 0.320 |
Why?
|
| Humans | 45 | 2025 | 93511 | 0.310 |
Why?
|
| Genital Neoplasms, Female | 2 | 2023 | 112 | 0.310 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 2017 | 0.300 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 175 | 0.300 |
Why?
|
| Dietary Supplements | 1 | 2010 | 131 | 0.300 |
Why?
|
| Skin | 3 | 2024 | 578 | 0.290 |
Why?
|
| Sexism | 2 | 2019 | 56 | 0.290 |
Why?
|
| Aged | 22 | 2024 | 20430 | 0.290 |
Why?
|
| Biological Products | 1 | 2010 | 178 | 0.260 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 7061 | 0.260 |
Why?
|
| Prostheses and Implants | 1 | 2007 | 123 | 0.260 |
Why?
|
| Adult | 20 | 2024 | 27918 | 0.250 |
Why?
|
| Prostate | 1 | 2010 | 416 | 0.240 |
Why?
|
| Bone and Bones | 1 | 2007 | 273 | 0.240 |
Why?
|
| Organs at Risk | 2 | 2016 | 48 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1775 | 0.220 |
Why?
|
| Cisplatin | 3 | 2018 | 568 | 0.220 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2024 | 31 | 0.220 |
Why?
|
| Nocebo Effect | 1 | 2024 | 3 | 0.220 |
Why?
|
| Mammography | 1 | 2007 | 458 | 0.220 |
Why?
|
| Radiation, Ionizing | 1 | 2024 | 123 | 0.210 |
Why?
|
| Drugs, Generic | 1 | 2024 | 21 | 0.210 |
Why?
|
| Dysbiosis | 1 | 2024 | 91 | 0.200 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 314 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 188 | 0.190 |
Why?
|
| Tumor Burden | 2 | 2017 | 321 | 0.190 |
Why?
|
| Heart | 3 | 2018 | 522 | 0.180 |
Why?
|
| Anxiety | 1 | 2024 | 337 | 0.180 |
Why?
|
| Young Adult | 7 | 2024 | 6930 | 0.170 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 62 | 0.170 |
Why?
|
| Hysterectomy | 2 | 2020 | 167 | 0.170 |
Why?
|
| Rectum | 3 | 2016 | 149 | 0.170 |
Why?
|
| Standard of Care | 1 | 2021 | 70 | 0.160 |
Why?
|
| Treatment Outcome | 10 | 2019 | 9098 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 2544 | 0.160 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2020 | 30 | 0.160 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2020 | 33 | 0.160 |
Why?
|
| Depression | 1 | 2024 | 544 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2019 | 59 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 1133 | 0.150 |
Why?
|
| Oximetry | 1 | 2020 | 90 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2020 | 2585 | 0.150 |
Why?
|
| Microbiota | 1 | 2024 | 425 | 0.150 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 109 | 0.150 |
Why?
|
| Breast | 2 | 2011 | 294 | 0.150 |
Why?
|
| Retrospective Studies | 10 | 2025 | 10164 | 0.150 |
Why?
|
| Dilatation | 1 | 2019 | 47 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 372 | 0.150 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 504 | 0.140 |
Why?
|
| Physicians, Women | 1 | 2019 | 58 | 0.140 |
Why?
|
| Constriction, Pathologic | 1 | 2019 | 207 | 0.140 |
Why?
|
| Urethral Neoplasms | 1 | 2018 | 10 | 0.140 |
Why?
|
| Postoperative Care | 2 | 2017 | 235 | 0.140 |
Why?
|
| Breath Holding | 1 | 2018 | 25 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2018 | 66 | 0.140 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 349 | 0.140 |
Why?
|
| Vagina | 1 | 2019 | 177 | 0.140 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 33 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 297 | 0.130 |
Why?
|
| Thoracic Wall | 2 | 2014 | 26 | 0.130 |
Why?
|
| Deoxycytidine | 1 | 2018 | 208 | 0.130 |
Why?
|
| Colon, Sigmoid | 1 | 2016 | 7 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 155 | 0.130 |
Why?
|
| Polycythemia Vera | 1 | 2016 | 22 | 0.130 |
Why?
|
| Urinary Bladder | 2 | 2016 | 260 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2020 | 443 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2016 | 28 | 0.120 |
Why?
|
| Hydroxyurea | 1 | 2016 | 231 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 91 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 939 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2016 | 87 | 0.120 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2365 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 624 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2016 | 150 | 0.120 |
Why?
|
| Lung | 2 | 2014 | 1366 | 0.110 |
Why?
|
| Contrast Media | 1 | 2020 | 988 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 402 | 0.110 |
Why?
|
| Oxygen | 1 | 2020 | 769 | 0.110 |
Why?
|
| United States | 5 | 2021 | 7619 | 0.110 |
Why?
|
| Radiotherapy Setup Errors | 1 | 2014 | 2 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1723 | 0.110 |
Why?
|
| Hematologic Diseases | 1 | 2015 | 77 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1448 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2021 | 1006 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1234 | 0.100 |
Why?
|
| Male | 13 | 2024 | 44553 | 0.100 |
Why?
|
| Patient Positioning | 1 | 2014 | 65 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2015 | 302 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 1170 | 0.100 |
Why?
|
| Equipment Design | 1 | 2014 | 416 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 306 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 394 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 145 | 0.090 |
Why?
|
| Surgical Instruments | 2 | 2014 | 62 | 0.090 |
Why?
|
| Radiodermatitis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 100 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 666 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1053 | 0.090 |
Why?
|
| Trigeminal Neuralgia | 1 | 2011 | 8 | 0.090 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2011 | 16 | 0.090 |
Why?
|
| Colony-Forming Units Assay | 1 | 2010 | 39 | 0.080 |
Why?
|
| Fatigue | 2 | 2024 | 181 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 876 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 165 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 985 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2010 | 154 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 608 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 813 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2010 | 279 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 5410 | 0.070 |
Why?
|
| Obesity | 2 | 2014 | 1018 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 165 | 0.060 |
Why?
|
| Adolescent | 4 | 2024 | 9606 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2010 | 700 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2715 | 0.060 |
Why?
|
| Cell Line | 1 | 2010 | 2464 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3476 | 0.060 |
Why?
|
| Cross Infection | 1 | 2007 | 155 | 0.060 |
Why?
|
| Wakefulness-Promoting Agents | 1 | 2024 | 1 | 0.050 |
Why?
|
| Placebo Effect | 1 | 2024 | 35 | 0.050 |
Why?
|
| Uncertainty | 1 | 2024 | 78 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2010 | 1741 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2755 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 259 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 170 | 0.050 |
Why?
|
| Mastectomy | 2 | 2016 | 262 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2014 | 4560 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2018 | 1524 | 0.050 |
Why?
|
| Respiration | 2 | 2018 | 269 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2016 | 756 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 1917 | 0.040 |
Why?
|
| Child | 3 | 2024 | 7355 | 0.040 |
Why?
|
| Bacteria | 1 | 2024 | 509 | 0.040 |
Why?
|
| Prone Position | 1 | 2020 | 61 | 0.040 |
Why?
|
| Uterus | 1 | 2021 | 227 | 0.040 |
Why?
|
| Attention | 1 | 2024 | 411 | 0.040 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2019 | 8 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 1906 | 0.040 |
Why?
|
| Women's Rights | 1 | 2019 | 8 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 620 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2014 | 811 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 25 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 77 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 68 | 0.040 |
Why?
|
| Spirometry | 1 | 2018 | 77 | 0.030 |
Why?
|
| Vincristine | 1 | 2018 | 99 | 0.030 |
Why?
|
| Survival Rate | 2 | 2013 | 1948 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 242 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 278 | 0.030 |
Why?
|
| Faculty, Medical | 1 | 2019 | 187 | 0.030 |
Why?
|
| Kinetics | 1 | 2019 | 1492 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2018 | 284 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 5898 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 154 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 100 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 390 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 3828 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 90 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 168 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 384 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2014 | 122 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2013 | 3829 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 841 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 1729 | 0.020 |
Why?
|
| Chicago | 1 | 2016 | 1464 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1161 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1007 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 362 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 206 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 85 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 884 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1701 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 579 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1922 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 217 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 1090 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 373 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 322 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2010 | 524 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1931 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1780 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1910 | 0.020 |
Why?
|
| Esthetics | 1 | 2007 | 50 | 0.020 |
Why?
|
| Pakistan | 1 | 2007 | 17 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2007 | 82 | 0.020 |
Why?
|
| Movement | 1 | 2007 | 304 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 889 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2007 | 454 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 2303 | 0.010 |
Why?
|